@AnnaFlorcia@sleepydragon01 Any thoughts on Darwin Management fund and their $2.4bn position in INSM? Think it’s a bet on other drugs in their pipeline and not necessarily TPIP?
@T_OConnell Have you heard/seen any thoughts from affiliate’s of Stanford Medicine re: Yutrepia? Saw the BSR LQDA/UTHR report. They had the largest scripts surveyed but relatively small Yutrepia scripts
@T_OConnell@alex_ahdoot@ValueSniper_670 @Austin__Vee On that note, what downside risks do you see here other than execution risk (lower sales/less market share taken than anticipated)
@T_OConnell Only if we can get some hype behind MVLA… jokes aside - are you only expecting this craze to last a day, or more so playing the IV crush if it moves sideways?
@jvb_xyz Since majority of this spare is KSA capacity, and given they are trying to sell down Aramco and have incentive to keep an elevated price - at what point is this not viewed as “spare capacity” that can come online at any time?
@econ_713@garquake Curious on your thoughts Peter re KSA voluntary cuts just announced. To what degree does this give potential to over tightening as you mentioned last week? And as I have seen others mention, I’m your opinion does this in any way undermine OPEC’s previous demand forecasts?
@T_OConnell Great call. This move IMO seems to be more algo driven given the markets current sentiment on the AI narrative + a nice technical setup. The company has solid fundamentals - so curious on your thoughts regarding where we are in the cycle of this trade?